Chemomab Therapeutics (NASDAQ:CMMB) Releases Earnings Results

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.64) earnings per share (EPS) for the quarter, FiscalAI reports.

Chemomab Therapeutics Stock Down 5.5%

CMMB stock opened at $1.55 on Thursday. Chemomab Therapeutics has a 52 week low of $0.92 and a 52 week high of $2.99. The stock has a market capitalization of $11.23 million, a P/E ratio of -0.73 and a beta of 0.80. The firm has a 50-day simple moving average of $1.58 and a 200-day simple moving average of $1.74.

Wall Street Analyst Weigh In

Several brokerages recently commented on CMMB. Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a research note on Saturday, October 3rd. Weiss Ratings raised shares of Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Check Out Our Latest Report on CMMB

About Chemomab Therapeutics

(Get Free Report)

Chemomab Therapeutics is an Israel-based clinical-stage biopharmaceutical company developing treatments for inflammatory and fibrotic diseases. Its research focuses on CCL24, a signaling protein the company believes contributes to inflammation and tissue scarring. The company’s lead candidate, CM-101, is a monoclonal antibody designed to block CCL24. Chemomab has studied the candidate in conditions including primary sclerosing cholangitis and systemic sclerosis. Chemomab was previously a privately held company and became publicly traded in 2021 through a merger with Anchiano Therapeutics.

Featured Articles

Earnings History for Chemomab Therapeutics (NASDAQ:CMMB)

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.